Potential of telomerase-specific oncolytic adenovirus as an immunogenic drug producing synergy with anti-PD-1 therapy

被引：0

作者：

Kanaya, Nobuhiko ^{[1
]}

Kuroda, Shinji ^{[1
]}

Morihiro, Toshiaki ^{[1
]}

Kubota, Tetsushi ^{[1
]}

Tazawa, Hiroshi ^{[1
]}

Kikuchi, Satoru ^{[1
]}

Nishizaki, Masahiko ^{[1
]}

Kagawa, Shunsuke ^{[1
]}

Urata, Yasuo ^{[2
]}

Fujiwara, Toshiyoshi ^{[1
]}

机构：

[1] Okayama Univ, Dept Grastroenterol Surg, Okayama, Japan

[2] Oncolys BioPharma Inc, Tokyo, Japan

来源：

CANCER SCIENCE | 2018年 / 109卷

关键词：

Oncolytic virus; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-3178

引用

页码：1059 / 1059

页数：1

共 50 条

[31] Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy
Chongxian Hou
Shenbao Shi
Mengjiao Gao
Jingsen Ji
Chengcheng Ma
Tianwei Wang
Taoliang Chen
Yang Liu
Jiasheng Zhong
Yaofeng Zheng
Jing’an Ye
Yiquan Ke
Journal of Neuro-Oncology, 2023, 165 : 79 - 90
[32] Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model
Kuryk, Lukasz
Mathlouthi, Sara
Wieczorek, Magdalena
Gad, Beata
Rinner, Beate
Malfanti, Alessio
Mastrotto, Francesca
Salmaso, Stefano
Caliceti, Paolo
Garofalo, Mariangela
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2024, 199
[33] Small molecule drug inhibition of PD-1 transcription is as effective as anti-PD-1 biologic blockade in cancer therapy
Rudd, Christopher E.
Rothstein, David
Taylor, Alison
JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
[34] Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
Wang, Xuanyi
Chai, Zixuan
Li, Yinghong
Long, Fei
Hao, Youjin
Pan, Guizhi
Liu, Mingwei
Li, Bo
GENES, 2020, 11 (04)
[35] The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
Xie, Xin
Lv, Jingwen
Zhu, Wei
Tian, Chao
Li, Jingfeng
Liu, Jiajia
Zhou, Hua
Sun, Chunyang
Hu, Zongfeng
Li, Xiaopeng
TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
[36] Enhanced Antitumor Efficacy of Oncolytic Adenovirus Co-Expressing IL-12 and shVEGF Combined with Anti-PD-1 in Renal Cell Carcinoma
Kim, Yunlim
Yoon, A-Rum
Yun, Chae-Ok
Kim, Choung-Soo
Lim, Bumjin
CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
[37] Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma
Amini-Adle, M.
Balme, B.
Dalle, S.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (12): : 802 - 803
[38] Expression of pRb and PD-L1 as potential predictive biomarkers for oncolytic adenovirus based gene therapy of urothelial carcinoma
Lau, Ryan
Chin, Curtis
Yu, Weibo
Grandi, Paola
Shen, Shihpei
Lai, Calvin
Rao, Jianyu
LABORATORY INVESTIGATION, 2019, 99
[39] Expression of pRb and PD-L1 as potential predictive biomarkers for oncolytic adenovirus based gene therapy of urothelial carcinoma
Lau, Ryan
Chin, Curtis
Yu, Weibo
Grandi, Paola
Shen, Shihpei
Lai, Calvin
Rao, Jianyu
MODERN PATHOLOGY, 2019, 32
[40] TUMOR TREATING FIELDS INDUCE IMMUNOGENIC CELL DEATH RESULTING IN ENHANCED ANTITUMOR EFFICACY WHEN COMBINED WITH ANTI-PD-1 THERAPY
Voloshin, T.
David, S.
Porat, Y.
Shteingauz, A.
Munster, M.
Kaynan, N.
Giladi, M.
Kirson, E.
Weinberg, U.
Palti, Y.
NEURO-ONCOLOGY, 2018, 20 : 272 - 272

← 1 2 3 4 5 →